BridgeBio in Focus: Diversification as a Recipe for Success in the Fight Against Genetic Defects
Reading Time: 3 minutes
BridgeBio Pharma is a biotechnology company focused on the discovery, development, testing, and provision of treatments for patients with genetic disorders. BridgeBio has successfully transitioned from a biotech company in the pure research and development phase to a company with a commercially successful product. The business model of BridgeBio, based on a broad and diversified pipeline, spreads the risk and offers immense potential. BridgeBio Pharma (NASDAQ: BBIO) specializes in the development of therapies for rare genetic diseases....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
